Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to get Screeners that run automatically with the results emailed to you! FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Roche Holdings Ltd ADR (RHHBY)

Roche Holdings Ltd ADR (RHHBY)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]

Fundamentals

See More
  • Market Capitalization, $K 367,580,032
  • Shares Outstanding, K 6,370,538
  • Annual Sales, $ 76,450 M
  • Annual Income, $ 15,542 M
  • EBIT $ 0 M
  • EBITDA $ 19,129 M
  • 60-Month Beta 0.44
  • Price/Sales 4.76
  • Price/Cash Flow 17.29
  • Price/Book 9.08
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm 0.00
  • Most Recent Earnings N/A on N/A
  • Next Earnings Date 01/29/26
  • Annual Dividend & Yield (Fwd) 0.87 (1.53%)
  • Most Recent Dividend 0.873 on 03/28/25
  • Sector Medical
  • INDUSTRY GROUPING Large Cap Pharma

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 16 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year N/A
  • Growth Rate Est. (year over year) unch

Price Performance

See More
Period Period Low Period High Performance
1-Month
52.3200 +10.28%
on 01/07/26
58.4000 -1.20%
on 02/04/26
+6.0900 (+11.80%)
since 01/06/26
3-Month
41.4300 +39.27%
on 11/07/25
58.4000 -1.20%
on 02/04/26
+16.4800 (+39.98%)
since 11/06/25
52-Week
34.7500 +66.04%
on 04/09/25
58.4000 -1.20%
on 02/04/26
+18.0900 (+45.67%)
since 02/06/25

Most Recent Stories

More News
Genentech’s Fenebrutinib Is the First Investigational Medicine in Over a Decade That Reduces Disability Progression in Primary Progressive Multiple Sclerosis (PPMS)

– Late-breaking Phase III FENtrepid results presented at ACTRIMS show investigational fenebrutinib met its primary endpoint of non-inferiority compared to the current standard of care, Ocrevus, in reducing...

RHHBY : 57.7000 (+1.01%)
Genentech Announces Positive Phase II Results for Its Dual GLP-1/GIP Receptor Agonist CT-388 in People Living With Obesity

- A once-weekly subcutaneous injection of CT-388 achieved a statistically significant placebo-adjusted weight loss of 22.5% (p < 0.001) at 48 weeks at the highest dose tested (24 mg), without reaching...

RHHBY : 57.7000 (+1.01%)
Genentech More than Doubles Investment in Holly Springs, North Carolina Manufacturing Facility

Genentech will more than double the initial investment in a state-of-the-art biomanufacturing facility in Holly Springs to approximately $2 billion, bolstering Roche and Genentech’s...

RHHBY : 57.7000 (+1.01%)
Looking to ‘Sell America’ Amid Fed Drama? Here’s 1 ETF to Buy.

'Sell America' fear is rising again, and this non-U.S. ETF could be a wise buy to stay diversified and invested globally while U.S. policy risks swirl.

BLK : 1,056.38 (+0.15%)
BABA : 162.51 (+3.01%)
DXY00 : 97.579 (-0.06%)
SIH26 : 78.935 (+2.65%)
GCG26 : 4,951.2s (+1.85%)
NVS : 156.42 (+1.60%)
RHHBY : 57.7000 (+1.01%)
HSBC : 89.29 (+2.79%)
TSM : 348.85 (+5.48%)
ASML : 1,413.01 (+4.66%)
$DXY : 97.63 (-0.19%)
AZN : 193.03 (+3.14%)
When Wall Street Rotates, Biotech Innovators Emerge: The Untapped Opportunities in Oncology

Market rotations are as old as Wall Street itself. When capital exits overheated sectors like big tech, it often finds its way into undervalued industries ripe for rediscovery. The latest shift, away from...

AZN : 193.03 (+3.14%)
PPCB : 0.1898 (-5.99%)
RHHBY : 57.7000 (+1.01%)
BMY : 61.99 (+4.15%)
FDA Approves Genentech’s Lunsumio VELO™ for Subcutaneous Use in Relapsed or Refractory Follicular Lymphoma

– Lunsumio VELO reduces administration time from 2-4 hours to approximately one minute – – Availability of Lunsumio VELO allows treatment aligned to people’s clinical...

RHHBY : 57.7000 (+1.01%)
Genentech Announces Agreement With U.S. Government

– Agreement with the U.S. government addresses prescription drug costs and encourages other wealthy nations to reward biopharmaceutical innovation – – Influenza...

RHHBY : 57.7000 (+1.01%)
Roche announces U.S. launch of next-generation cobas 6800/8800 systems and software, enhancing laboratory efficiency and testing capabilities

INDIANAPOLIS , Dec. 16, 2025 /PRNewswire/ -- Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today the launch of the new cobas ® 6800/8800 systems version 2.0 and software version 2.0.1,...

ROG : 105.93 (+3.75%)
RHHBY : 57.7000 (+1.01%)
Genentech’s Giredestrant Reduced Risk of Invasive Disease Recurrence or Death by 30% in ER-positive Early-Stage Breast Cancer

– Giredestrant is the only oral SERD to show superior invasive disease-free survival in the adjuvant setting, marking the first significant endocrine therapy advance in over 20 years – ...

RHHBY : 57.7000 (+1.01%)
Genentech Presents Lunsumio Data Showing Potential Across Earlier Treatment Lines in Indolent and Aggressive Lymphomas

– Lunsumio in combination with lenalidomide may offer an effective treatment in relapsed or refractory follicular lymphoma based on first data from single-arm cohort of Phase III CELESTIMO study –...

RHHBY : 57.7000 (+1.01%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy and ranks in the Top 1% of all short term signal directions.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Basel, Switzerland-based Roche Holding Ltd. is a leading health care company focused on developing and commercializing innovative diagnostic and therapeutic products and services, which enable early detection and prevention of diseases as well as their treatment and monitoring. The company conducts its...

See More

Key Turning Points

3rd Resistance Point 59.4533
2nd Resistance Point 58.7167
1st Resistance Point 58.2083
Last Price 57.7000
1st Support Level 56.9633
2nd Support Level 56.2267
3rd Support Level 55.7183

See More

52-Week High 58.4000
Last Price 57.7000
Fibonacci 61.8% 49.3657
Fibonacci 50% 46.5750
Fibonacci 38.2% 43.7843
52-Week Low 34.7500

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar